Tag: Vyriad Inc.
Vyriad, Inc. says Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates published in the journal Vaccine
eNewsChannels NEWS: -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
Former CIO and Treasurer to Mayo Clinic, Harry Hoffman named to Vyriad, Inc. Board of Directors
eNewsChannels NEWS: -- yriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.
